* FTSE 100 up 0.7%, FTSE 250 up 0.2%
* AstraZeneca biggest boost to main index
* RBS slides after reporting Q3 loss (Adds company news items, analyst comments, updates share prices)
By Muvija M and Shashwat Awasthi
Oct 24 (Reuters) - London's FTSE 100 rose on Thursday along with its European counterparts, helped by strong French manufacturing data and gains in AstraZeneca after a 2019 forecast upgrade.
After rising to session highs following data from France, the main bourse eased slightly after another survey showed employment in Germany's private sector fell for the first time in six years in October. conflicting data come at a time of existing fears over global economic growth, as multiple unfavourable events including the U.S.-China trade tussle and Brexit play out.
In the past two weeks UK shares have been volatile with major Brexit developments including Prime Minister Boris Johnson striking a new Brexit deal with the European bloc and lawmakers at home forcing his hand into asking for another extension to the divorce.
'U.S.-CHINA AND BREXIT IN LIMBO'
The FTSE 100, whose components rake in more than two-thirds of their earnings in U.S. dollars, is on course for its best weekly gain since early June, as uncertainties over the course of UK's EU departure have dented the value of sterling.
AstraZeneca AZN.L gained 3%, its biggest one-day rise in three months, after the pharmaceutical giant raised its annual product sales forecast for the second time this year. and decision tools provider Relx REL.L and industrial software company Aveva AVV.L added 2.5% each following trading updates.
"There's not been a huge catalyst for markets this week. Earnings are largely topping beaten-down estimates. U.S.-China and Brexit are in limbo," Markets.com analyst Neil Wilson said.
On the other end of the spectrum was Royal Bank of Scotland RBS.L that skidded 3% as it swung to a third-quarter loss due to a fresh 900 million pound provision to settle mis-selling claims.
A notable mid-cap performer was Kaz Minerals KAZ.L that jumped 7% after record third-quarter copper production as it ramped up operations at its biggest mines in Kazakhstan. Patient Capital Trust WPCT.L , formerly run by high-profile money manager Neil Woodford, jumped 22% as the company appointed asset manager Schroders SDR.L as its new portfolio manager.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.